ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory...
Read MoreAccomplished biopharma executive brings nearly 25 years of experience in business development, capital formation, and enterprise strategy to this role...
Read MoreStudy shows pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischemic encephalopathy, as well as neurodegenerative diseases such...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreData confirm elevated inflammatory biomarkers in newborns with Hypoxic Ischemic Encephalopathy (HIE) and demonstrate a predictable pharmacokinetic profile for RLS-0071...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreNORFOLK, Va. – February 25, 2025 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated...
Read MoreData demonstrates pegtarazimod’s ability to reduce inflammation and significantly increase survival rates in multiple preclinical models of aGVHD Norfolk, Va...
Read More